Author/Editor		Bren, Andrej F; Kandus, Aljoša; Varl, Janez; Buturović, Jadranka; Ponikvar, Rafael; Primožič, Stanislav; Ivanovich, Peter
Title		Epoetin omega vs epoetin alfa in the correction of anemia in hemodialysis patients
Type		članek
Source		In: Buturović-Ponikvar J, Bren AF, editors. Zbornik 2. slovenski nefrološki kongres z mednarodno udeležbo ob 30. letnici dialize in transplantacije ledvic v Sloveniji; 2000 sep 27-30; Brdo pri Kranju. Ljubljana: Klinični center, Klinični oddelek za nefrologijo,
Publication year		2000
Volume		str. 215-8
Language		eng
Abstract		The objective of our study was to evaluate and compare the effectiveness and safe ty of epoetin omega (produced in BHK cells) and epoetin alfa (produced in CHO cells) in sustaining the correction of anemia in maintenance hemodialysis patients. The study was a prospective, controlled crossover completed in 38 stable patients treated with both epoetins for 24 weeks. Both epoetins were administered subcutaneously after each hemodialysis with the aim of maintaining a target hemoglobin level between 100 and 120 g/L (hematocrit 30 to 35%). Iron was supplemented intravenously as ferric saccharate. The mean weekly dose of epoetin omega/kg BW was 67 +- 43 U. The mean weekly dose of epoetin alfa/kg BW was 86 +- 53 U. The average of all mean values of hemoglobin during treatment with epoetin omega was 114 +- 7 g/L (hematocrit 34 +- 2%), and during treatment with epoetin alfa 113 +- 7 g/L (hematocrit 33 +- 2%) (NS). The quotients between mean fortnight doses of epoetin omega per kg BW and hemoglobin were lower than during the epoetin alfa treatment period (p<0.002). An integrated comparison of administered doses (area under the doses curve, AUC doses) of epoetin omega and alfa showed that a lower quantity of epoetin omega was given (p<0.0005). A median AUC dose for epoetin omega was 1481 and for epoetin alfa 1667 U/kg BW/24 weeks. We concluded that the differences in corrective doses of epoetin omega and epoetin alfa could be attrib uted to their molecular structure and related pharmacokinetic and pharmacodynamic properties, because the patients' clinical condition, as well as iron status and other parameters, did not differ in two study periods. We noted no serious side effect with either epoetin omega or with epoetin alfa.
Descriptors		HEMODIALYSIS ANEMIA EPOETIN ALFA HEMOGLOBINOMETRY